Carboplatin
- Generic Name
- Carboplatin
- Brand Names
- Paraplatin
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12N2O4Pt
- CAS Number
- 41575-94-4
- Unique Ingredient Identifier
- BG3F62OND5
Overview
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting. Carboplatin was granted FDA approval on 3 March 1989.
Background
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting. Carboplatin was granted FDA approval on 3 March 1989.
Indication
Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.
Associated Conditions
- Advanced Cervical Cancer
- Advanced Endometrial Cancer
- Advanced Esophageal Cancers
- Advanced Head and Neck Cancer
- Advanced Melanoma
- Advanced Non-Small Cell Lung Cancer (NSCLC)
- Advanced Ovarian Carcinoma
- Advanced Sarcoma
- Malignant Pleural Mesothelioma (MPM)
- Merkel Cell Carcinoma
- Metastatic Breast Cancer
- Refractory Hodgkin Lymphoma
- Retinoblastoma
- Thymoma
- Advanced Bladder cancer
- Advanced Small cell lung cancer
- Advanced Testicular cancer
- Advanced Thymoma
- Refractory Non-Hodgkin's lymphoma
Clinical Trials
View More Clinical Trials
Sign in to access the complete clinical trial database with detailed study information.
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2003/04/03 | Phase 2 | Completed | |||
2003/03/07 | Phase 2 | Completed | |||
2003/03/07 | Phase 3 | UNKNOWN | |||
2003/03/07 | Phase 2 | Completed | |||
2003/03/07 | Phase 3 | Withdrawn | |||
2003/02/06 | Phase 3 | Terminated | |||
2003/02/06 | Phase 3 | Withdrawn | |||
2003/01/28 | Phase 2 | Completed | |||
2003/01/28 | Phase 1 | Completed | |||
2003/01/27 | Phase 1 | Completed |
FDA Approved Products
View More FDA Products
Sign in to access additional FDA-approved products with detailed regulatory information.
Product Name | Manufacturer | Route | Strength | Approved | NDC Code |
|---|
No FDA products found
No FDA products found for this drug
EMA Approved Products
View More EMA Products
Sign in to access additional EMA-approved products with authorization details.
Product Name | EMA Number | Auth. Holder | Country | Drug Type | Status | Issued | Opinion | Revision |
|---|
No EMA products found
No EMA products found for this drug
HSA Approved Products
View More HSA Products
Sign in to access additional HSA-approved products with regulatory information.
Product Name | Manufacturer | Dosage Form | Strength | Approved | Approval Number |
|---|
No HSA products found
No HSA products found for this drug
NMPA Approved Products
View More NMPA Products
Sign in to access additional NMPA-approved products with approval information.
Product Name | Approval Number | Manufacturer | Dosage Form | Trade Name | Strength | Type | Status | Date | Import |
|---|
No NMPA products found
No NMPA products found for this drug
PPB Approved Products
Product Name | Registration Code | Company | Category | Sale Type | Registration Date |
|---|
No PPB products found
No PPB products found for this drug
TGA Approved Products
View More TGA Products
Sign in to access additional TGA-approved products with licensing information.
Product Name | ARTG ID | Sponsor | Status | Registration Date | Ingredient |
|---|
No TGA products found
No TGA products found for this drug